The IFT46 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line. This product provides a loss-of-function model for investigating the role of IFT46 in cellular processes. The polyclonal format captures a heterogeneous pool of edited cells, reflecting the diverse outcomes of CRISPR/Cas9-mediated gene disruption without single-cell cloning. This population is suitable for experiments where pooled knockout efficacy is sufficient, enabling robust and reproducible phenotypic screening.
The HT29 cell line is a widely used model of human colorectal adenocarcinoma, originally isolated from a primary tumor. These cells exhibit epithelial morphology and are commonly employed to study epithelial barrier function, colorectal cancer biology, and intestinal cell differentiation. HT29 cells retain the capacity to polarize and form tight junctions under appropriate culture conditions, making them valuable for investigating signaling pathways that influence intestinal epithelial homeostasis and tumorigenesis. The introduction of an IFT46 knockout into this well-characterized background creates a relevant platform for exploring the intersection of ciliary biology and colorectal cancer.
IFT46 encodes a core subunit of the intraflagellar transport complex B (IFT-B) essential for anterograde ciliary transport and ciliogenesis. It physically interacts with IFT52, IFT88, IFT20, and IFT57 within the IFT-B complex, and associates with kinesin-2 motors (KIF3A/KIF3B/KAP3). Knockout of IFT46 disrupts primary cilium formation and attenuates Hedgehog signaling by impairing trafficking and processing of SMO and GLI transcription factors (GLI1, GLI2), thereby reducing expression of targets like PTCH1. IFT46 expression is modulated by RFX transcription factors (RFX1-3) and tied to cell cycle regulation.
HT29 cells typically form primary cilia under serum-starved conditions, and genetic ablation of IFT46 in this colorectal cancer context provides a direct means to assess how loss of ciliary function influences tumor cell behavior. Given the emerging implications of primary cilia in cancer progression, this knockout model enables dissection of cilia-dependent versus cilia-independent tumorigenic processes. It may particularly illuminate the contribution of IFT46 to colorectal adenocarcinoma phenotypes, including proliferation, migration, and epithelial-to-mesenchymal transition. Additionally, the model serves as a tool for studying ciliopathies such as cranioectodermal dysplasia (Sensenbrenner syndrome) and short-rib thoracic dysplasia, where IFT46 mutations are causative, by providing a human cell-based platform to investigate disease mechanisms.
Researchers can use these IFT46 knockout HT29 cells for immunofluorescence detection of ciliary markers (Arl13b, acetylated ??-tubulin) to quantify ciliation, transcriptomic (RT-qPCR, RNA-seq) and protein (Western blot) analyses of pathway components, Hedgehog signaling reporter assays, and functional assays for proliferation and migration. Co-immunoprecipitation studies can assess IFT-B complex integrity. These cells are also applicable to drug screens for ciliogenesis modulators. For further information, contact Ascent Research.
